Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17785642 | 0.86 | ERN1 (0.47) | ERN1MAPTPKMMAPK1ALDH1A1 | |
| SCHEMBL4301198 | 0.83 | ATM (0.47) | ERN1MAPTALDH1A1CYP3A4KDM4E | |
| SCHEMBL16370945 | 0.81 | ATM (0.48) | ERN1MAPTPKMALDH1A1CYP3A4 | |
| SCHEMBL2536509 | 0.81 | MAPT (0.59) | MAPTPKMMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL29495221 | 0.81 | MAPT (0.59) | MAPTPKMMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL535172 | 0.80 | ALDH1A1 (0.50) | ERN1MAPTPKMMAPK1ALDH1A1 | |
| SCHEMBL2721914 | 0.79 | ALDH1A1 (0.53) | ERN1MAPTPKMMAPK1ALDH1A1 | |
| SCHEMBL7759334 | 0.79 | MAPT (0.53) | MAPTPKMMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL30598678 | 0.79 | MAPT (0.53) | MAPTPKMMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL4397890 | 0.79 | MAPT (0.53) | MAPTPKMMAPK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125346-A1 | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4709711-A1 | ISOQUINOLINONE DERIVATIVES AND 4H-QUINOLIZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | Beone Medicines I GmbH (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4612128-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3227271-B1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RES LAB (KR) | 2025-08-13 | — | — | EP | disclosed |
| CN-120129677-A | Compounds and their use for the treatment of heme lesions | 百时美施贵宝公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| US-7605157-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2007-07-12 | — | — | US | disclosed |
| US-7208490-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208490-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208490-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1551849-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2004-08-19 | — | — | US | disclosed |
| WO-2004031195-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | QTRT1, QTRT2, NQO2 | ERN1 1952/4885MAPT 2763/4885PKM 3790/4885 |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | QTRT1, QTRT2, NQO2 | ERN1 1952/4885MAPT 2763/4885PKM 3790/4885 |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | ERN1 3101/4885MAPT 4138/4885PKM 603/4885 |
| US-20260125346-A1 | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | NR3C1, NR3C2, PIK3R4 | ERN1 2143/4885MAPT 1022/4885PKM 3282/4885 |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | HBG1, HBG2, HBB | ERN1 3101/4885MAPT 4138/4885PKM 603/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | ERN1 4586/4885MAPT 3444/4885PKM 703/4885 |
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | MET, MERTK, AXL | ERN1 1944/4885MAPT 2736/4885PKM 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.